Korro Bio, Inc. (KRRO) Financial Statements (2026 and earlier)

Company Profile

Business Address 60 FIRST STREET
CAMBRIDGE, MA 02141
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments126,095166,15083,097130,707220,341217,355
Cash and cash equivalent55,643166,15051,95479,635220,341200,158
Short-term investments70,452 31,14351,072 17,197
Restricted cash and investments 3,563    
Receivables1,700    805
Prepaid expense   1,6082,3842,5522,132
Other current assets   255185102199
Other undisclosed current assets3,7373,0152,5331,4722,069864
Total current assets:131,532172,72887,493134,748225,064221,355
Noncurrent Assets
Operating lease, right-of-use asset23,83627,15028,98031,35030,551 
Property, plant and equipment27,71015,6652,7395,5227,2871,762
Long-term investments and receivables36,959  11,719  
Long-term investments36,959  11,719  
Restricted cash and investments3,4063,4061,6991,6991,820 
Other noncurrent assets2,7972,714   101
Other undisclosed noncurrent assets   327320  
Total noncurrent assets:94,70848,93533,74550,61039,6581,863
TOTAL ASSETS:226,240221,663121,238185,358264,722223,218
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,16317,4929,0058,84912,1694,458
Accounts payable3,9927,2803,1142,7485,5061,219
Accrued liabilities6,17110,2125,8916,1016,6633,239
Deferred revenue3,513   14,06848,152
Debt   10,000833  
Other liabilities      170
Other undisclosed current liabilities1,2841,9912,0211,747397 
Total current liabilities:14,96019,48321,02611,42926,63452,780
Noncurrent Liabilities
Long-term debt and lease obligation   4,16743,01845,597180
Long-term debt, excluding current maturities   4,16714,16715,000180
Liabilities, other than long-term debt50,86532,26926,85087 2,900
Deferred revenue5,912    2,900
Other liabilities1,4721,0538987  
Operating lease, liability43,48131,21626,76128,85130,597 
Other undisclosed noncurrent liabilities     (30,597) 
Total noncurrent liabilities:50,86532,26931,01743,10545,5973,080
Total liabilities:65,82551,75252,04354,53472,23155,860
Equity
Equity, attributable to parent160,415169,91169,195130,824192,491167,358
Common stock9835353431
Additional paid in capital426,724352,908331,023310,936287,829236,161
Accumulated other comprehensive income (loss)268 (198)(62)2754
Accumulated deficit(266,586)(183,005)(261,665)(180,085)(95,399)(68,888)
Total equity:160,415169,91169,195130,824192,491167,358
TOTAL LIABILITIES AND EQUITY:226,240221,663121,238185,358264,722223,218

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues2,271 314,06836,98428,947
Realized investment gains (losses)   3(23)84138
Gross profit:2,271 314,06836,98428,947
Operating expenses(94,181)(84,534)(83,002)(98,099)(64,534)(49,622)
Other undisclosed operating income (loss)  (3)   
Operating loss:(91,910)(84,534)(83,002)(84,031)(27,550)(20,675)
Nonoperating income8,4703,3892,3781479907
Investment income, nonoperating   1,327397994 
Gain (loss), foreign currency transaction, before tax   (5)16(4)7
Other nonoperating income (expense)8,4703,3891,056(266)  
Interest and debt expense   (961)(764)  
Other undisclosed income from continuing operations before equity method investments, income taxes     84 
Loss from continuing operations before equity method investments, income taxes:(83,440)(81,145)(81,585)(84,648)(26,476)(20,668)
Other undisclosed income (loss) from continuing operations before income taxes   3(23)  
Loss from continuing operations before income taxes:(83,440)(81,145)(81,582)(84,671)(26,476)(20,668)
Income tax expense (benefit)(141)(27)2(15)(35) 
Loss from continuing operations:(83,581)(81,172)(81,580)(84,686)(26,511)(20,668)
Loss before gain (loss) on sale of properties:(84,686)(26,511)(20,668)
Other undisclosed net income      1,922
Net loss attributable to parent:(83,581)(81,172)(81,580)(84,686)(26,511)(18,746)
Preferred stock dividends and other adjustments      (1,054)
Net loss available to common stockholders, diluted:(83,581)(81,172)(81,580)(84,686)(26,511)(19,800)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(83,581)(81,172)(81,580)(84,686)(26,511)(18,746)
Other comprehensive income (loss)2685(136)(89)(27)54
Comprehensive loss:(83,313)(81,167)(81,716)(84,775)(26,538)(18,692)
Other undisclosed comprehensive loss, net of tax, attributable to parent (5)    
Comprehensive loss, net of tax, attributable to parent:(83,313)(81,172)(81,716)(84,775)(26,538)(18,692)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: